Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: What does an aborted trial tell us?

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 5, 2013, Pages 671-675

  Gontero, Paolo ^a   Fiorito, Chiara ^a   Oderda, Marco ^a   Pappagallo, Giovanni ^b   Brausi, Maurizio ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b Noale Hospital   (Italy)

^c AUSL Modena   (Italy)

Author keywords

CIS; Endovesical therapy; Gemcitabine; Non muscle invasive bladder cancer

Indexed keywords

GEMCITABINE; SODIUM CHLORIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CARCINOMA; BLADDER CARCINOMA IN SITU; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; CYTOLOGY; DERMATITIS; DRUG WITHDRAWAL; DYSURIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MALE; NAUSEA; OVERALL SURVIVAL; PERINEAL PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC ALLERGY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA IN SITU; CYSTITIS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84879456423     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.03.011     Document Type: Article

References (18)

1. Hudson M.A., Herr H.W. Carcinoma in situ of the bladder. J Urol 1995, 153:564-572.
2. Lamm D.L. Carcinoma in situ. Urol Clin North Am 1992, 19:499-508.
3. Lamm D.L., Herr H., Jakse G., et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol 1998, 4:130-135.
4. Sylvester R.J., Van der Meijden A.P., Witjes J.A., et al. Bacillus Calmette-Guerin vs. chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. J Urol 2005, 174:86-91.
5. Koya M.P., Simon M.A., Soloway M.S. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006, 175:2004-2010.
6. Joudi F.N., Smith B.J., O'Donnell M.A., et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006, 175:1634-1639.
7. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004, 46:339-343.
8. Maffezzini M., Campodonico F., Canepa G., et al. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low-, or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol 2007, 51:956-961.
9. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002, 20:3193-3198.
10. Gunelli R., Bercovich E., Nanni O., et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: A translational study. Br J Cancer 2007, 97:1499-1504.
11. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacilli Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006, 24:2729-2734.
12. Trotti A., Colevas A.D., Setser A., et al. CTCAE ver. 3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
13. Chen K., Shan M. Optimal and minimax three-stage designs for phase II oncology clinical trials. Contemp Clin Trials 2008, 29:32-41.
14. De Reijke T.M., Kurth K.H., Sylvester R.J., et al. Bacillus Calmette-Guerin vs. epirubicin for primary, secondary, or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J Urol 2005, 173:405-409. European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
15. Bartoletti R., Cai T., Gacci M., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a Phase II prospective multicenter study. Urology 2005, 66:726-731.
16. Mohanty N.K., Nayak R.L., Vasudeva P., et al. Intravesical gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 2008, 26:616-619.
17. Porena M., Del Zingaro M., Lazzeri M., et al. Bacillus Calmette-Guérin vs. gemcitabine for intravesical therapy in high-risk superficial bladder cancer: A randomized prospective study. Urol Int 2010, 84:23-27.
18. Böhle A., Leyh H., Frei C., et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: A randomized, double-blind, placebo-controlled phase III multicenter study. Eur Urol 2009, 56:495-503. S274 Study Group.